⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251428 | 0.69 | — | — | |
| SCHEMBL2950040 | 0.69 | — | — | |
| SCHEMBL3545694 | 0.67 | — | — | |
| SCHEMBL1480708 | 0.67 | — | — | |
| SCHEMBL515026 | 0.57 | — | — | |
| SCHEMBL570870 | 0.57 | — | — | |
| SCHEMBL17319722 | 0.55 | — | — | |
| SCHEMBL7531583 | 0.55 | — | — | |
| SCHEMBL1112757 | 0.55 | — | — | |
| SCHEMBL1112761 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10082 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | claimed |
| WO-2024138018-A1 | TREATMENT OF GEMIN5-MEDIATED DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | claimed |
| CN-118203585-A | Pharmaceutical use of ENPP1 inhibitors | 上海翊石医药科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-118201916-A | Piperazinylsulfonylaryl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118201933-A | Tri-fused ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | claimed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-118084864-A | PRMT4 inhibitor, and pharmaceutical composition, pharmaceutical preparation and application thereof | 北京福元医药股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | claimed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | claimed |
| US-4522943-A | ANTISECRETORY ANTIULCER AGENT | BRISTOL-MYERS COMPANY (US) | 1985-06-11 | — | — | US | claimed |
| US-4517366-A | ETHANEDIIMIDAMIDE, HISTAMINE HYDROGEN RECEPTOR ANTAGONISTS | BRISTOL-MYERS COMPANY (US) | 1985-05-14 | — | — | US | claimed |
| US-4507485-A | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity | BRISTOL-MYERS COMPANY (US) | 1985-03-26 | — | — | US | claimed |
| US-4503051-A | ANTIULCER, HISTAMINE H2-ANTAGONIST | BRISTOL-MYERS COMPANY (US) | 1985-03-05 | — | — | US | claimed |
| US-4443449-A | Arylcyclobutylalkylamines and anti-depression composition and methods using same | THE BOOTS COMPANY LIMITED (GB) | 1984-04-17 | — | — | US | claimed |
| US-4440933-A | HISTAMINE H2-RECEPTOR ANTAGONISTS | BRISTOL-MYERS COMPANY (US) | 1984-04-03 | — | — | US | claimed |
| EP-0099122-A2 | Compositions comprising pepstatin and an histamine H2-receptor antagonist having an enhanced antiulcer activity | Bristol-Myers Company (US) | 1984-01-25 | — | — | EP | claimed |
| EP-0000106-B1 | 2-ALKYL NICOTINOIDS AND PROCESSES FOR THEIR PRODUCTION AND USE | PHILIP MORRIS INCORPORATED (US) | 1982-02-17 | — | — | EP | claimed |
| US-4312873-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1982-01-26 | — | — | US | claimed |